

1 **Utility of the pareidolia test in mild cognitive impairment with Lewy bodies and**
2 **Alzheimer's disease**

3 Running Title: Pareidolia test in MCI-LB and MCI-AD

4 Calum A Hamilton^{1*}, Fiona E Matthews², Louise M Allan³, Sally Barker¹, Joanna Ciafone¹,
5 Paul C Donaghy¹, Rory Durcan¹, Michael J Firbank¹, Sarah Lawley¹, John T O'Brien⁴,
6 Gemma Roberts^{1,5}, John-Paul Taylor¹, Alan J Thomas¹

7 ¹Translational and Clinical Research Institute, Newcastle University, UK

8 ²Population Health Sciences Institute, Newcastle University, UK

9 ³College of Medicine and Health, Exeter University, UK

10 ⁴Department of Psychiatry, University of Cambridge, UK

11 ⁵Nuclear Medicine Department, Newcastle upon Tyne Hospitals NHS Foundation Trust,
12 Newcastle upon Tyne, UK

13 *Corresponding Author: calum.hamilton@newcastle.ac.uk 3rd Floor Biomedical Research
14 Building, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, NE4
15 5PL, UK

16 **Word Count:** 3530 (manuscript) 249 (abstract)

17 **Acknowledgements:** None

18 **Funding Statement:** This work was supported by Alzheimer's Research UK (Grant Number
19 ARUK-PG3026-13) and the NIHR Newcastle Biomedical Research Centre. GE Healthcare
20 provided the FP-CIT radioligand for this investigator-led study.

21 **Conflicts of interest:** None

22

1 **Abstract**

2 **Objectives**

3 Previous research has identified that dementia with Lewy bodies (DLB) has abnormal
4 pareidolic responses which are associated with severity of visual hallucinations (VH), and
5 the pareidolia test accurately classifies DLB with VH. We aimed to assess whether these
6 findings would also be evident at the earlier stage of mild cognitive impairment (MCI) with
7 Lewy bodies (MCI-LB) in comparison to MCI due to AD (MCI-AD) and cognitively healthy
8 comparators.

9 **Methods**

10 One-hundred and thirty-seven subjects were assessed prospectively in a longitudinal study
11 with a mean follow-up of 1.2 years (max = 3.7): 63 MCI-LB (22% with VH) and 40 MCI-AD
12 according to current research diagnostic criteria, and 34 healthy comparators. The pareidolia
13 test was administered annually as a repeated measure.

14 **Results**

15 Probable MCI-LB had an estimated pareidolia rate 1.2-6.7 times higher than MCI-AD.
16 Pareidolia rates were not associated with concurrent VH, but had a weak association with
17 total score on the North East Visual Hallucinations Inventory. The pareidolia test was not an
18 accurate classifier of either MCI-LB (AUC = 0.61), or VH (AUC = 0.56). There was poor
19 sensitivity when differentiating MCI-LB from controls (41%) or MCI-AD (27%), though
20 specificity was better (91 and 89%, respectively).

21 **Conclusions**

22 Whilst pareidolic responses are specifically more frequent in MCI-LB than MCI-AD,
23 sensitivity of the pareidolia test is poorer than in DLB, with fewer patients manifesting VH at
24 the earlier MCI stage. However, the high specificity and ease of use may make it useful in
25 specialist clinics where imaging biomarkers are not available

1 **Keywords:** Mild cognitive impairment; dementia with Lewy bodies; visual hallucinations;
2 pareidolia

3 **Key Points:**

4 1) Pareidolia responses to ambiguous visual stimuli may be a surrogate for visual
5 hallucinations

6 2) Pareidolias are more common in dementia with Lewy bodies than in Alzheimer's
7 disease

8 3) We found an increased rate of pareidolias in mild cognitive impairment with Lewy
9 bodies than in Alzheimer's disease or healthy comparators

10 4) Misperceptions in the pareidolia test are reasonably specific to mild cognitive
11 impairment with Lewy bodies, but these may lack sensitivity at early stages

12

1 **Background**

2 Visual hallucinations (VH) are a feature of several psychiatric, neurological and
3 ophthalmological disorders¹. In dementia, visual hallucinations are particularly associated
4 with the clinical syndrome of dementia with Lewy bodies (DLB) with an estimated prevalence
5 of 55-78%². Complex VH, characteristically of well-formed images of people or animals, are
6 one of the core clinical features differentiating clinically-suspected Lewy body aetiology from
7 the competing diagnosis of Alzheimer's disease (AD) in both dementia³ and mild cognitive
8 impairment (MCI)⁴.

9 VH may be context-dependent, and therefore difficult to quantify in clinical or research
10 settings; these are often assessed through clinical interview after self-report by the patient,
11 or report of this apparent phenomenon by an informant. This may limit the detection of visual
12 hallucinations in the absence of insight by the patient, or unavailability of an informant.
13 Comparable visual illusory phenomena (pareidolias, misperceptions of meaningful forms
14 within ambiguous or visually-noisy stimuli) which may be elicited on demand in an
15 experimental setting have therefore been proposed as proxies of VH.

16 These pareidolic misidentifications have been shown to be more common in DLB than in AD
17 or healthy controls, and to be positively correlated with the frequency of VH⁵. This research
18 suggested that human and animal faces and bodies were the most common illusions in
19 these tasks, supporting a phenomenological link to DLB-associated complex VH. A
20 simplified pareidolia test, where participants report the presence or absence of illusory faces
21 amongst visual noise scenes, has similarly shown to be reliable in discriminating DLB from
22 AD (sensitivity of 81% and specificity of 92%). Pareidolia responses were more common in
23 DLB than AD and healthy controls, were more common within cases of DLB with clinically-
24 judged VH, and positively correlated with neuropsychiatric inventory (NPI) hallucination (of
25 any sensory modality) scores⁶.

1 While the pareidolia test shows apparent utility in discriminating hallucinations and DLB at
2 the dementia stage, this utility has not yet been demonstrated in the prodromal stages of
3 cognitive decline of MCI with Lewy bodies (MCI-LB) when cognitive impairments have begun
4 to manifest. While neuropsychiatric symptoms, including visual hallucinations, may be
5 present at this stage, they may be less common than in DLB while the full clinical syndrome
6 is still emerging^{7,8}.

7 We therefore aimed to test the rate of pareidolic misidentifications in MCI-LB in contrast to
8 MCI due to AD (MCI-AD) and age-matched healthy control subjects using the noise
9 pareidolia test, and to consider the utility of this test in detecting clinically-judged complex
10 VH and MCI-LB. Based on the above findings from the dementia literature, our hypotheses
11 to test were: 1) MCI-LB patients would produce more pareidolic responses than MCI-AD or
12 controls; 2) pareidolic responses would be more common in clinically-judged visual
13 hallucinators than non-hallucinators, and correlate with severity of hallucinations; 3) the
14 pareidolia test would acceptably classify clinically-judged visual hallucinators, and MCI-LB
15 cases.

16

1 **Methods**

2 ***Participants***

3 **Patients:**

4 Recruitment for this longitudinal cohort has been described in depth previously⁹. Briefly,
5 participants over 60 years old were recruited from memory services, neurology and geriatric
6 medical clinics in North East England. Prospective participants provided informed consent
7 before undergoing more detailed screening by a research study medical doctor, and MRI
8 brain imaging. Those with possible frontotemporal or vascular aetiologies, parkinsonism
9 preceding onset of cognitive symptoms by more than one year, dementia, or absence of
10 objective cognitive impairment at screening were excluded. Inclusion criteria were age \geq 60
11 years, and diagnosis of MCI at screening in accordance with NIA-AA criteria; concern about,
12 and objective evidence of decline in cognition with maintained ability to function
13 independently¹⁰, requiring a Clinical Dementia Rating (CDR) no higher than 0.5.

14 **Controls:**

15 Healthy participants were recruited from families of patients and local research involvement
16 services and similarly screened as with patients undergoing medical review, neurological
17 examination, MRI brain imaging, and comprehensive neurocognitive assessment. Inclusion
18 criteria were being age \geq 60 years and cognitively healthy, with no known brain disease and
19 a CDR of 0.

20 All participants, both patients and controls, were required to be medically stable on study
21 entry. Local deprivation was calculated for each participant from the 2019 English Indices of
22 Multiple Deprivation (IMD); IMD scores are formed into country-wide deciles so that a decile
23 of one corresponds to living within one of the 10% most deprived neighbourhoods in
24 England, and a decile of 10 being within the 10% least deprived neighbourhoods¹¹.

1 **Design**

2 Participants were assessed annually in a longitudinal design with repeated clinical interview
3 with patient and informant (where available), medical review, and neurocognitive
4 assessment. Differential clinical diagnoses (as below) were reviewed annually based on
5 clinical interview, medical review, and imaging findings.

6 **Procedure**

7 **Clinical assessment and imaging**

8 Participants underwent a detailed clinical assessment at baseline including physical and
9 neurological examination, and at annual follow-up visits. Informants were also interviewed if
10 available to provide further information. Interviews included the Geriatric Depression Scale,
11 Clinician Assessment of Fluctuations, Dementia Cognitive Fluctuations Scale,
12 Neuropsychiatric Inventory (NPI) for informants, North-East Visual Hallucinations Inventory
13 (NEVHI) for patients, Unified Parkinson's Disease Rating Scale – Part III, and Mayo Sleep
14 Questionnaire. Instrumental Activities of Daily Living were rated by the informant (blind to
15 cause, and therefore sensitive to non-cognitive causes of dependence), and the CDR was
16 completed by the clinical assessor based on this interview.

17 ¹²³I-FP-CIT SPECT imaging was offered to all participants at baseline as previously
18 detailed¹², and repeated at one year follow-up. Images were visually rated as normal or
19 abnormal by a five-person consensus panel of FP-CIT imaging experts, blind to clinical
20 information. ¹²³I-mIBG cardiac sympathetic innervation imaging (cardiac mIBG) was also
21 offered to all participants at baseline; delayed images (taken ~ 4 hours post-injection with
22 medium energy collimators) were quantified with a heart:mediastinum ratio cut-off of < 1.86
23 considered abnormal based on local data from healthy controls¹³.

24 **Clinical diagnosis and differential classification**

25 A three-person consensus panel of experienced old age psychiatrists (AJT, PCD, JPT)
26 independently reviewed clinical research notes provided from the clinical interview and

1 assessment annually to confirm the presence of all-cause MCI according to NIA-AA criteria¹⁰
2 at baseline.

3 Each panel member also independently rated the presence or absence of each of the four
4 core clinical features of DLB (parkinsonism, REM sleep behaviour disorder, fluctuating
5 cognition, and complex visual hallucinations) based on research clinical notes and blind to
6 imaging results. Core clinical features and imaging results were then incorporated along with
7 clinical diagnosis to classify patients as MCI-AD (MCI, with no core clinical features of DLB,
8 normal FP-CIT and mIBG imaging), possible MCI-LB (MCI with either one core clinical
9 feature of DLB and normal imaging, or no core clinical features with abnormal FP-CIT and/or
10 mIBG imaging), or probable MCI-LB (MCI with two or more core clinical features of DLB, or
11 one clinical feature with one or more imaging abnormalities). These diagnoses were
12 therefore consistent with current guidelines for classification of MCI-LB in research settings⁴.
13 Diagnoses and classifications were repeated and updated after each follow-up assessment.
14 In the case that participants were seen to have lost functional independence at follow-up
15 assessment, all-cause criteria for dementia were considered¹⁴. No further follow-up was
16 undertaken after diagnosis of dementia.

17 **Neurocognitive assessment**

18 A detailed neurocognitive assessment battery was administered to all participants separately
19 from the clinical review, including the Addenbrooke's Cognitive Examination – Revised
20 (ACE-R) as a test of global cognitive function from which Mini Mental State Examination
21 (MMSE) was derived, the National Adult Reading Test (NART) was administered at baseline
22 as an estimator of premorbid function. Additional assessments were administered, but not
23 considered for this work, having being detailed elsewhere⁸.

24 **Pareidolia test**

25 The 40-item visual noise pareidolia test⁶ was administered at baseline and repeated at
26 annual follow-up in the same manner: forty black-and-white visual noise images were

1 presented sequentially on laminated cards. Individually differing human face images were
2 presented within the noise in eight of these stimuli, and the remaining 32 contained only
3 visual noise. After being shown three example stimuli to become acquainted with the task
4 (two with faces, one without), participants were allowed up to 30 seconds to view each of the
5 40 test pages and asked to report if they did, or did not, see a face in each image. The test
6 administrator recorded responses, out of view and without feedback or correction to the
7 participant, as either correct (correctly identifying a face which was present, or correctly
8 identifying a non-face stimulus), missed (missing a face which was present), or a pareidolia
9 (where the participant identified a face as being present in a noise-only image). When
10 providing ambiguous responses (e.g. “maybe”), participants were prompted to provide either
11 a “yes” or “no” answer. As in previous studies, the count of pareidolia responses was the
12 outcome of interest.

13 **Analysis**

14 To assess group differences in the production of pareidolia responses, incorporating repeat
15 assessments over time to maximise data availability and account for any time trends (e.g.
16 increased pareidolia rates as MCI progressed), a generalised linear mixed model with log
17 link function was estimated using the *lme4* package for *R* software. Model fit was assessed
18 by the Akaike Information Criterion (AIC). Subject-specific random intercept and time slope
19 were included, as were relevant covariates by block entry, with continuous variables centred
20 to a meaningful reference value, mean integer or median to aid in intercept interpretation:
21 time since baseline assessment (in years), presence of visual impairment reported at health
22 screening, global cognitive function (ACE-R score, time-varying; centre at 84), premorbid
23 function (NART estimated IQ; centre at 100), gender (female as reference), age (centre at
24 75 years), education (years in education, centre at 13), and local deprivation (IMD decile,
25 centre at 5). Up to third-degree polynomials were assessed for all continuous variables to
26 allow for non-linear effects. Diagnostic group (**Model 1**) and VH presence (time-varying,
27 where applicable) as rated by the clinical panel (**Model 2**) were included as hypothesis-

1 testing fixed effects, with group x time interactions included when supported by
2 improvements in model fit.

3 Significance was considered as $p < .05$ for hypothesis-testing effects, after controlling for
4 relevant covariates.

5 To assess the sensitivity and specificity of the pareidolia task in classifying a) clinically-
6 judged visual hallucinations and b) MCI-LB (possible or probable), receiver operating
7 characteristic (ROC) curves were plotted, and the area under the ROC curve (AUC) derived
8 with the *plotROC* package for *R* software. Sensitivity and specificity of this test in
9 differentiating MCI-LB were assessed using cut-offs previously identified from the dementia
10 stages: ≥ 5 pareidolia errors (vs. MCI-AD) or ≥ 3 errors (vs. controls)⁶. Classification
11 analyses made use of baseline test data only, to eliminate the influence of further decline on
12 pareidolia error rates.

1 **Results**

2 ***Baseline characteristics***

3 One-hundred and three MCI patients and 34 healthy controls were available for inclusion
4 (**Figure 1**). A median of two observations (baseline and 1-year follow-up) were available for
5 each participant (Mean follow-up time = 1.2 years, SD = 0.99, max = 3.7 years).

6 Demographics and baseline task performance are presented in **Table 1**. Consistent with the
7 respective dementia syndromes, there was a gender disparity between MCI-AD and MCI-LB
8 groups, with the former being predominantly female, and the latter predominantly male. VH
9 were not as prevalent in MCI-LB as previously observed in DLB, being identified in 14 out of
10 64 cases (22%) at baseline at this earlier stage.

11

1 ***Pareidolia analysis***

2 Second-degree polynomials (linear and quadratic terms) were supported for the fixed effect
3 of time only. No interactions with diagnosis were supported, and the resulting best-fitting
4 models are presented in **Table 2**, with covariate effects in **Supplementary Table S1**. **Model**
5 **1** assessed diagnostic group differences in rate of producing pareidolia responses. The
6 expected pareidolia count at the intercept (reference group: MCI-AD) was 0.79 (95% CI:
7 0.38 – 1.67). Healthy controls did not significantly differ in their test performance from MCI-
8 AD, with expected pareidolia counts of 0.60. Probable MCI-LB were significantly more likely
9 than MCI-AD to falsely perceive faces within noise stimuli (1.22 to 6.69 times the rate of
10 pareidolias: expected count of 2.26). While possible MCI-LB had a similar point estimate to
11 probable MCI-LB, there was more uncertainty in this estimate, and so this was not
12 significantly different from MCI-AD (0.97 to 7.13 times the rate of pareidolias: expected count
13 of 2.07). There was a slight positive growth in pareidolia response rates over time initially,
14 though this was attenuated by the quadratic term over longer time periods, which may reflect
15 the exclusion of dementia cases after follow-up.

16 These associations remained after controlling for the presence or absence of clinically-
17 judged complex visual hallucinations at baseline or follow-up as a time-varying predictor
18 (**Model 2**), which was not a significant predictor of pareidolic responses. The variance
19 inflation factor for each component was low (all < 2 across both models), suggesting there
20 was little collinearity between predictors.

21 In both models the marginal R^2 was relatively low compared to the conditional R^2 ,
22 suggesting that much of the variance in this measure could be attributed to individual-level
23 differences in task performance. This is supported by the expected pareidolia values being
24 low, even in MCI-LB groups, compared to the true observed range of pareidolia responses
25 produced at baseline (see **Table 1**).

1 Repeated-measure correlations found no significant association between pareidolia
2 responses and NPI-measured hallucinations score as rated by informants ($r(71) = 0.03$, $p =$
3 $.782$), but did support a weak positive correlation between pareidolia production and total
4 score on the NEVHI as rated by patients ($r(120) = 0.22$, $p = .017$).

5 ***Classification analysis***

6 Despite broad group differences in pareidolia response rates, the pareidolia test was found
7 to have poor utility in classifying both hallucinating MCI cases specifically (AUC = 0.56), and
8 MCI-LB (AUC = 0.61) in general (see **Supplementary Figure S1**). Using cut-offs identified
9 from the dementia stage⁶, the noise pareidolia test had a sensitivity of 27% (95% CI: 16-
10 40%) and specificity of 89% (75-97%) in differentiating MCI-LB from MCI-AD (cut-off ≥ 5
11 pareidolia responses), and sensitivity of 41% (28-55%) and specificity of 91% (76-98%) in
12 differentiating MCI-LB from healthy controls (cut-off ≥ 3).

1 **Discussion**

2 ***Summary of aims and findings***

3 We aimed to assess if differences in performance on the noise pareidolia test observed
4 between DLB and AD would also be present in the respective MCI stages of these.

5 We found only limited support for our hypotheses; probable MCI-LB were found to make
6 more pareidolic misperceptions when completing this test than MCI-AD and controls,
7 consistent with previous findings in DLB⁶ but this association was not clearly found in the
8 possible MCI-LB group.

9 There was no clear association between rates of pareidolic misperceptions and the presence
10 of complex visual hallucinations as assessed by an expert clinical panel, contrary to the
11 hypothesis. No association was found between pareidolia rates and hallucination severity (of
12 any sensory modality) assessed by the NPI, but a weak association was found more
13 specifically with simple and complex visual hallucination severity as measured by the
14 NEVHI.

15 Finally, the utility of the noise pareidolia test in classifying either MCI-LB or clinical visual
16 hallucinations was not supported; while the noise pareidolia test was able to differentiate
17 MCI-LB from MCI-AD or healthy controls with good specificity, cut-off values from DLB had
18 low sensitivity when applied to MCI-LB.

19 ***Interpretation***

20 These results partially extend previous findings to suggest that differences in the experience
21 of pareidolias between DLB and AD^{5,6} may already be apparent at the MCI stages of these
22 aetiologies, with a higher rate of pareidolic responses in MCI-LB, though this was limited to
23 the most diagnostically clear sub-group of probable MCI-LB. However, there was
24 considerable subject-level variability in the reporting of perceived faces not attributable to
25 any considered variable. Consequently, the noise pareidolia test had less predictive value in
26 classifying either a Lewy body syndrome, or visual hallucinations in MCI, in comparison to

1 the dementia stage⁶. However, as a simple assessment with relatively low time cost and
2 good specificity for MCI-LB, the pareidolia test may have value as an accessible early
3 screening test for suspected MCI-LB in settings where more accurate but costly markers
4 such as FP-CIT or mIBG imaging are not available.

5 VH were much less common in this MCI-LB sample than is typical in DLB (22% vs. 55-
6 78%)², and pareidolias also occurred at higher rates in previous studies than in our own
7 (mean of 3.5 in MCI-LB vs. 7.3 in DLB)⁶ which may account for the limited utility of the noise
8 pareidolia task in classifying these and MCI-LB. As our MCI patients were in the prodromal
9 stage it remains likely that their clinical symptoms will continue to develop with more VH
10 emerging closer to the onset of, and during, dementia. Pareidolic misidentifications may
11 precede the eventual clinical manifestation of VH as a simple form of visual illusion
12 comparable to the visual perceptual dysfunctions and progressive decline commonly
13 observed in DLB^{15,16} and MCI-LB¹⁷, which have been shown to predict the eventual onset of
14 visual hallucinations in DLB¹⁸. Future work may consider whether pareidolia rates in non-
15 hallucinating MCI predict the eventual emergence of complex VH by the onset of dementia;
16 the prospective identification of complex visual hallucinations may have value in clinical and
17 research settings due to the previously-reported association between this particular clinical
18 feature of DLB and progressive cognitive decline in MCI¹⁹.

19 Several factors could account for both individual- and group differences in the production of
20 pareidolia responses; previous research has suggested that an increased reliance upon prior
21 knowledge in discrimination of ambiguous visual imagery may mediate the associations
22 between Lewy body disorders and visual hallucinations²⁰. When approaching the pareidolia
23 test with a clearly defined objective (to discriminate faces from noise) some individuals, and
24 particularly those with MCI-LB may therefore place relatively more weighting on this prior
25 expectation, therefore increasing the rate of misperceptions even in the absence of clinically
26 manifest complex visual hallucinations.

1 The high variability in rates of pareidolias even within MCI-AD could suggest that, despite
2 uniformity in instructions, individuals may still vary in their understanding and approach to
3 the test; some participants may favour a false positive-minimising strategy (only reporting
4 unambiguous perception of faces), while others may favour a false negative-minimising
5 strategy (reporting faces in the absence of a true misperception to avoid missing one). With
6 the diagnostic effect sizes being relatively small in the MCI stages, individual-level factors
7 such as these may contribute to the limited classification utility in prodromal DLB.

8 While functional independence was highly variable at baseline in the MCI group with some
9 particularly low IADL scores, these were assessed to include all contributions to functional
10 dependence, including motor impairment (previously found to be correlated with baseline
11 IADL scores in MCI-LB, while cognitive scores were not)¹⁷ and social or cultural factors (e.g.
12 the patient's contributions to housework were limited even prior to onset of any cognitive
13 impairment). Despite some low IADL scores, all patients were judged to have MCI at
14 baseline as evidenced by a CDR < 1.

15 ***Strengths and limitations***

16 These data include a moderately-sized cohort with detailed clinical assessment and imaging
17 for aetiological classification. We have made use of flexible modelling approaches to
18 incorporate repeated measures to appropriately account for individual-level effects, and
19 controlled for several anticipated confounding variables.

20 However, considerable variability was observed in this sample which was not explained by
21 fixed effects. While we controlled for visual impairment reported at medical review, no
22 objective measures of visual acuity were available, though previous research found no
23 association between visual acuity and pareidolia rates in this test⁶. As a prospective cohort,
24 it is not yet apparent which patients will develop VH by the time of onset of dementia, only
25 those who have already done so (a minority of the MCI-LB group); while this clinical
26 symptom was modelled as a time-varying predictor, it is not clear at this stage if an

1 increased pareidolia rate in MCI may precede or predict the eventual clinical manifestation of
2 VH.

3 **Conclusions**

4 Probable MCI-LB had a higher rate of pareidolia responses in the visual noise pareidolia
5 task than MCI-AD, who did not clearly differ from healthy controls. The relationship between
6 hallucinations and pareidolia responses was not as clear as in dementia, with comparisons
7 limited by low rates of hallucinations in MCI. Due to considerable inter-individual variation in
8 task performance, the noise pareidolia test did not accurately classify MCI-LB or VH.

1 **References**

- 2 1. O'Brien J, Taylor JP, Ballard C, et al. Visual hallucinations in neurological and
3 ophthalmological disease: pathophysiology and management. *J Neurol Neurosurg*
4 *Psychiatry*. 2020;91(5):512-519.
- 5 2. Cummings J, Ballard C, Tariot P, et al. Pimavanserin: Potential Treatment For Dementia-
6 Related Psychosis. *J Prev Alzheimers Dis*. 2018;5(4):253-258.
- 7 3. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy
8 bodies: Fourth consensus report of the DLB Consortium. *Neurology*. 2017;89(1):88-100.
- 9 4. McKeith IG, Ferman TJ, Thomas AJ, et al. Research criteria for the diagnosis of prodromal
10 dementia with Lewy bodies. *Neurology*. 2020;94:1-13.
- 11 5. Uchiyama M, Nishio Y, Yokoi K, et al. Pareidolias: complex visual illusions in dementia with
12 Lewy bodies. *Brain*. 2012;135(8):2458-2469.
- 13 6. Mamiya Y, Nishio Y, Watanabe H, et al. The Pareidolia Test: A Simple Neuropsychological
14 Test Measuring Visual Hallucination-Like Illusions. *PLoS One*. 2016;11(5):e0154713.
- 15 7. Donaghy PC, Taylor J-P, O'Brien JT, et al. Neuropsychiatric symptoms and cognitive profile in
16 mild cognitive impairment with Lewy bodies. *Psychol Med*. 2018;48(14):2384-2390.
- 17 8. Donaghy PC, Ciafone J, Durcan R, et al. Mild cognitive impairment with Lewy bodies:
18 neuropsychiatric supportive symptoms and cognitive profile. *Psychol Med*. 2020:1-9.
- 19 9. Schumacher J, Taylor J-P, Hamilton CA, et al. Quantitative EEG as a biomarker in mild
20 cognitive impairment with Lewy bodies. *Alzheimers Res Ther*. 2020;12(1):82.
- 21 10. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to
22 Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's
23 Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's &*
24 *Dementia*. 2011;7(3):270-279.
- 25 11. Noble S, McLennan D, Noble M, et al. The English Indices of Deprivation 2019: Research
26 Report. In: Ministry of Housing CaLG, ed2019.

- 1 12. Thomas AJ, Donaghy PC, Roberts G, et al. Diagnostic accuracy of dopaminergic imaging in
2 prodromal dementia with Lewy bodies. *Psychol Med.* 2019;49(3):396-402.
- 3 13. Roberts G, Lloyd JJ, Jefferson E, et al. Uniformity of cardiac (123)I-MIBG uptake on SPECT
4 images in older adults with normal cognition and patients with dementia. *J Nucl Cardiol.*
5 2019.
- 6 14. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's
7 disease: Recommendations from the National Institute on Aging-Alzheimer's Association
8 workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's & Dementia.*
9 2011;7(3):263-269.
- 10 15. Mosimann UP, Mather G, Wesnes KA, O'Brien JT, Burn DJ, McKeith IG. Visual perception in
11 Parkinson disease dementia and dementia with Lewy bodies. *Neurology.* 2004;63(11):2091-
12 2096.
- 13 16. Smirnov DS, Galasko D, Edland SD, Filoteo JV, Hansen LA, Salmon DP. Cognitive decline
14 profiles differ in Parkinson disease dementia and dementia with Lewy bodies. *Neurology.*
15 2020.
- 16 17. Hamilton CA, Matthews FE, Donaghy PC, et al. Cognitive decline in mild cognitive
17 impairment with Lewy bodies or Alzheimer's disease: a prospective cohort study. *Am J*
18 *Geriatr Psychiatry.* 2020.
- 19 18. Hamilton JM, Landy KM, Salmon DP, Hansen LA, Masliah E, Galasko D. Early visuospatial
20 deficits predict the occurrence of visual hallucinations in autopsy-confirmed dementia with
21 Lewy bodies. *Am J Geriatr Psychiatry.* 2012;20(9):773-781.
- 22 19. Hamilton CA, Matthews FE, Donaghy PC, et al. Prospective predictors of decline versus
23 stability in mild cognitive impairment with Lewy bodies or Alzheimer's disease. *Psychol Med.*
24 2020.

1 20. Zarkali A, Adams RA, Psarras S, Leyland LA, Rees G, Weil RS. Increased weighting on prior
2 knowledge in Lewy body-associated visual hallucinations. *Brain communications*.
3 2019;1(1):fcz007.

4

5

1 **Table and Figure Captions:**

2 Table 1. Baseline characteristics and task performance

	Control (n=34)	MCI-AD (n=40)	Possible MCI-LB (n=20)	Probable MCI-LB (n=43)	P Value
<i>Female Gender</i>	10 (29.4%)	23 (57.5%)	9 (45.0%)	7 (16.3%)	< .001 ^a
<i>Age</i>	74.2 (7.45)	76.2 (7.54)	74.1 (7.95)	74.9 (6.36)	.598 ^b
<i>Years in Education</i>	14 [8.5, 24]	11 [10, 20]	11 [9, 25]	11 [9, 21]	.007 ^c
<i>Local Deprivation Decile</i>	6.5 [1, 10]	6 [1, 10]	3.5 [1, 10]	5 [1, 10]	.078 ^c
<i>Instrumental Activities of Daily Living</i>	-	8 [2, 8]	7 [3, 8]	6 [4, 8]	.012 ^c
<i>National Adult Reading Test Estimated Full-Scale IQ</i>	114 (8.64)	109 (12.3)	102 (11.4)	108 (9.54)	< .001 ^b
<i>Mini Mental State Examination</i>	28.5 (1.13)	26.9 (2.05)	26.0 (2.97)	26.4 (2.47)	< .001 ^b
<i>Addenbrooke's Cognitive Examination – Revised, Total</i>	92.7 (4.3)	82.4 (8.3)	78.0 (11.3)	83.0 (9.2)	< .001 ^b
<i>Neuropsychiatric Inventory – Total</i>	-	5 [0, 34]	3 [0, 44]	15 [0, 52]	.011 ^c
<i>Neuropsychiatric Inventory – Hallucinations</i>	-	0 [0, 1]	0 [0, 4]	0 [0, 8]	.006 ^c
<i>North-East Visual Hallucinations Inventory</i>	0 [0, 3]	0 [0, 7]	1 [0, 15]	0 [0, 16]	< .001 ^c
<i>Pareidolia Task – Pareidolias</i>	0 [0, 5]	1 [0, 16]	2 [0, 20]	2 [0, 14]	.007 ^c
<i>Pareidolia Task – Misses</i>	0 [0, 1]	0 [0, 3]	0 [0, 3]	0 [0, 2]	.371 ^c
<i>Visual Hallucinations</i>	0 (0%)	0 (0%)	4 (20.0%)	10 (23.3%)	< .001 ^a
<i>Any Visual Impairment</i>	2 (5.9%)	3 (7.5%)	2 (10.0%)	2 (4.7%)	.868 ^a

3 Mean (SD), Median [Range], or Count (%).

4 ^aChi-square test

5 ^bANOVA

6 ^cKruskal-Wallis test

7

1 Table 2. Generalised linear mixed models estimating pareidolia response production
 2 differences between diagnostic groups (Model 1) and hallucinators (Model 2). Intercept as
 3 expected count, fixed effects as incidence rate ratio.

	Model 1.			Model 2.		
Fixed Effects (reference group/value)	Incidence Rate Ratio[†]	95% CI	p	Incidence Rate Ratio	95% CI	p
<i>Intercept (MCI-AD)</i>	0.79	0.38 – 1.67	.542	0.79	0.38 – 1.67	.537
<i>Healthy Control (vs. MCI-AD)</i>	0.76	0.30 – 1.92	.557	0.77	0.30 – 1.96	.584
<i>Possible MCI-LB (vs. MCI-AD)</i>	2.62	0.97 – 7.13	.059	2.83	1.02 – 7.85	.046
<i>Probable MCI-LB (vs. MCI-AD)</i>	2.86	1.22 – 6.69	.016	3.05	1.27 – 7.35	.013
<i>Time, Linear Term</i>	1.58	1.01 – 2.45	.043	1.55	1.00 – 2.41	.051
<i>Time², Quadratic Term</i>	0.79	0.69 – 0.91	.001	0.80	0.69 – 0.92	.002
<i>Visual Hallucinations Present (vs. Absent)</i>	-	-	-	0.67	0.28 – 1.58	.357
<i>Controlling for: visual impairment, gender, global cognitive function[‡], premorbid intelligence[§], age, education, and deprivation (see Supplementary Table S1).</i>						
Random Effects						
σ^2	0.84			0.84		
Observations	271			271		
Marginal R ² / Conditional R ²	0.211 / 0.796			0.208 / 0.799		

4 [†]Baseline expected error rate at intercept, incidence rate ratio for all other effects


5 [‡]Addenbrooke's Cognitive Examination – Revised

6 [§]National Adult Reading Test – Estimated Full-Scale IQ

7

8

9



1


2 Figure 1. Recruitment flowchart for healthy controls and mild cognitive impairment (MCI)

3 groups

- 1 Supplementary Table S1. Generalised linear mixed models estimating pareidolia response
 2 production differences between diagnostic groups (Model 1) and hallucinators (Model 2).
 3 Intercept as expected count, fixed effects as incidence rate ratio.

	Model 1.			Model 2.		
Fixed Effects (reference group/value)	Incidence Rate Ratio	95% CI	p	Incidence Rate Ratio	95% CI	p
<i>Intercept (MCI-AD)</i> [†]	0.79	0.38 – 1.67	.542	0.79	0.38 – 1.67	.537
<i>Healthy Control (vs. MCI-AD)</i>	0.76	0.30 – 1.92	.557	0.77	0.30 – 1.96	.584
<i>Possible MCI-LB (vs. MCI-AD)</i>	2.62	0.97 – 7.13	.059	2.83	1.02 – 7.85	.046
<i>Probable MCI-LB (vs. MCI-AD)</i>	2.86	1.22 – 6.69	.016	3.05	1.27 – 7.35	.013
<i>Time, Linear Term</i>	1.58	1.01 – 2.45	.043	1.55	1.00 – 2.41	.051
<i>Time², Quadratic Term</i>	0.79	0.69 – 0.91	.001	0.80	0.69 – 0.92	.002
<i>Visual Impairment Present (vs. Absent)</i>	2.44	0.71 – 8.40	.156	2.45	0.71 – 8.51	.157
<i>Global Cognition (vs. 84 score)</i> [‡]	1.00	0.97 – 1.03	.768	0.99	0.96 – 1.02	.677
<i>Male Gender</i>	0.62	0.31 – 1.25	.181	0.61	0.30 – 1.23	.168
<i>Age (vs. 75 years)</i>	1.06	1.02 – 1.11	.006	1.06	1.02 – 1.11	.006
<i>Education (vs. 13 years)</i>	1.01	0.91 – 1.12	.861	1.00	0.90 – 1.12	.954
<i>Premorbid Function (vs. 100 IQ)</i> [§]	0.96	0.93 – 0.99	.017	0.96	0.93 – 0.99	.025
<i>Deprivation Decile (vs. decile 5)</i>	1.07	0.96 – 1.19	.221	1.07	0.96 – 1.19	.241
<i>Visual Hallucinations Present (vs. Absent)</i>	-	-	-	0.67	0.28 – 1.58	.357
Random Effects						
σ^2	0.84			0.84		
Observations	271			271		
Marginal R ² / Conditional R ²	0.211 / 0.796			0.208 / 0.799		

- 4 [†]Baseline expected error rate
 5 [‡]Addenbrooke's Cognitive Examination – Revised
 6 [§]National Adult Reading Test – Estimated Full-Scale IQ
 7



1

- 2 Supplementary Figure S1. Receiver operating characteristics curves for the utility of the
 3 noise pareidolia test in classifying clinically-judged visual hallucinators, and clinically-
 4 classified mild cognitive impairment with Lewy bodies.